CINECA IRIS Institutional Research Information System

CLERICO, Marinella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.311
AS - Asia 9.554
EU - Europa 8.977
SA - Sud America 1.396
AF - Africa 430
OC - Oceania 77
Continente sconosciuto - Info sul continente non disponibili 48
Totale 34.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.926
SG - Singapore 3.924
CN - Cina 2.351
IT - Italia 2.000
DE - Germania 1.253
VN - Vietnam 1.096
BR - Brasile 1.087
FR - Francia 897
IE - Irlanda 843
SE - Svezia 782
FI - Finlandia 591
UA - Ucraina 564
GB - Regno Unito 546
KR - Corea 544
IN - India 306
HK - Hong Kong 289
AT - Austria 277
JP - Giappone 242
CA - Canada 226
PL - Polonia 215
ES - Italia 209
NL - Olanda 187
SN - Senegal 146
ID - Indonesia 131
DK - Danimarca 121
AR - Argentina 109
BD - Bangladesh 102
RU - Federazione Russa 101
MX - Messico 99
TR - Turchia 88
IQ - Iraq 83
GR - Grecia 72
BE - Belgio 64
AU - Australia 63
ZA - Sudafrica 55
PK - Pakistan 49
EC - Ecuador 48
CH - Svizzera 45
IR - Iran 45
EU - Europa 44
EG - Egitto 41
MA - Marocco 38
MU - Mauritius 38
SA - Arabia Saudita 38
UZ - Uzbekistan 34
CO - Colombia 32
CL - Cile 30
IL - Israele 30
RO - Romania 28
CZ - Repubblica Ceca 26
PH - Filippine 26
PT - Portogallo 25
NO - Norvegia 24
PE - Perù 24
TW - Taiwan 24
VE - Venezuela 24
DZ - Algeria 22
TN - Tunisia 21
UY - Uruguay 19
JO - Giordania 18
KE - Kenya 16
LT - Lituania 16
TH - Thailandia 16
AZ - Azerbaigian 14
NP - Nepal 14
PY - Paraguay 14
AL - Albania 13
BG - Bulgaria 12
NG - Nigeria 12
NZ - Nuova Zelanda 12
RS - Serbia 12
AE - Emirati Arabi Uniti 11
CR - Costa Rica 11
JM - Giamaica 11
LB - Libano 11
MY - Malesia 11
CI - Costa d'Avorio 10
KG - Kirghizistan 9
BH - Bahrain 8
HU - Ungheria 8
MK - Macedonia 8
BO - Bolivia 7
SI - Slovenia 7
BY - Bielorussia 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
GT - Guatemala 6
OM - Oman 6
PS - Palestinian Territory 6
TT - Trinidad e Tobago 5
BB - Barbados 4
CY - Cipro 4
HN - Honduras 4
KZ - Kazakistan 4
QA - Qatar 4
BA - Bosnia-Erzegovina 3
BW - Botswana 3
CG - Congo 3
EE - Estonia 3
GE - Georgia 3
Totale 34.721
Salva come PNG Salva come JPEG
Città #
Singapore 2.140
San Jose 1.601
Chandler 1.316
Beijing 1.055
Ashburn 981
Dublin 823
Santa Clara 701
Ann Arbor 564
Fairfield 376
Houston 350
Jacksonville 346
Medford 305
Ho Chi Minh City 294
The Dalles 290
Fremont 283
Turin 271
Nyköping 269
Lauterbourg 268
Torino 264
Princeton 262
Columbus 259
Los Angeles 257
Villeurbanne 250
Wilmington 247
Hong Kong 242
Vienna 239
Hanoi 231
Milan 224
Dearborn 220
Dallas 213
Seoul 211
Hefei 196
Woodbridge 194
Warsaw 188
Munich 183
Buffalo 165
Dong Ket 145
Tokyo 145
New York 133
Helsinki 132
Seattle 127
Guangzhou 121
Cambridge 120
Boston 113
Boardman 110
Redwood City 108
Jakarta 93
Council Bluffs 91
São Paulo 89
Rome 84
Frankfurt am Main 74
Madrid 71
Washington 65
Bengaluru 64
London 64
Toronto 63
Nuremberg 61
Düsseldorf 57
Pisa 56
Verona 55
Hangzhou 53
Orem 53
Turku 51
Amsterdam 48
Redondo Beach 48
Shanghai 47
Da Nang 46
Lappeenranta 44
Paris 44
Brussels 40
Chicago 39
Montreal 39
Naples 38
San Diego 38
Baghdad 36
Chennai 36
Nanjing 36
Norwalk 36
Rio de Janeiro 35
Falls Church 34
Manchester 34
Chengdu 32
Haiphong 29
San Francisco 29
Istanbul 27
San Mateo 26
Belo Horizonte 25
Brasília 25
Curitiba 25
Groningen 25
Johannesburg 25
Bologna 24
Mexico City 24
Mumbai 23
Silver Spring 23
Atlanta 22
Brooklyn 22
Jinan 22
Pune 21
Stockholm 21
Totale 19.864
Salva come PNG Salva come JPEG
Nome #
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 769
Randomized trial of thymectomy in myasthenia gravis 669
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 634
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 569
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 455
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 429
Computer assisted interactive learning in medical education: flipped classrooms of clinical neurology for medicine students 409
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 393
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 276
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 263
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis 262
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 245
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 241
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 240
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry 235
Influence of cigarette smoking on ALS outcome: A population-based study 231
D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient 230
Digital therapeutics in neurology 230
Computational modeling of the immune response in multiple sclerosis using epimod framework 214
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 212
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 211
Natalizumab in Multiple Sclerosis: Long-Term Management 201
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 195
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 194
Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail 189
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 188
Online Validation of a Battery of Questionnaires for the Assessment of Family Functioning and Related Factors 180
CHARACTERIZATION OF AUTOREACTIVE TCR REPERTOIRE IN PATIENTS AFFECTED BYMULTIPLE SCLEROSIS. 178
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 178
To switch therapies in RRMS: why and when? A real-life multicentre study 176
Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic 176
Treatment response to interferon beta: Biological (MxA protein or IL-10 mRNA level) or MRI indicators? 173
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 171
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 170
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 167
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. 166
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 166
Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort 166
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 165
Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis 163
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question 163
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series 163
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 160
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 159
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 158
Longitudinal alteration of gut microbiome composition in subjects with Multiple Sclerosis during Dimethyl Fumarate therapy: a one-year follow-up study 156
A new computational workflow to guide personalized drug therapy 156
T helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β 156
Associations between socioemotional alterations, quality of life, and social functioning in multiple sclerosis: A scoping review 156
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis 154
Estrogen receptor-alpha regulates epigenetic changes on genomic regulatory regions: potential biomarkers in multiple sclerosis outcomes 152
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 151
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up 151
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 150
Comorbidities affect treatment choice and persistence in RRMS: a real-life multicenter study 149
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 148
The Use of Social Media and Digital Devices Among Italian Neurologists 148
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 148
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 147
Dementia care and COVID-19 pandemic: a necessary digital revolution 147
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 146
Adherence to interferon-beta treatment and results of therapy switching 145
A real-world study of Alemtuzumab in a cohort of Italian patients 145
Switching to alemtuzumab from fingolimod or other therapies: impact of wash-out period on disease activity 145
Epigenetic therapy for Friedreich ataxia. 144
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 144
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 144
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab 144
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 143
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 143
Prognostic influence of pre-morbid smoking habits, diabetes, arterial hypertension and vascular risk profile on phenotype and outcome of ALS patients: a population-based study. 142
Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy 142
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 142
Family functioning and multiple sclerosis: Study protocol of a multicentric italian project 141
T HELPER 22 CELLS INCREASE IN MULTIPLE SCLEROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 140
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 140
Estrogen Receptor Alpha- Associated Genomic Regions Are Potential Core of T Cell Subtypes Identity 139
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 139
Comparative effectiveness of Cladribine tablets vs other drugs in relapsing-remitting multiple sclerosis: an approach merging randomized controlled trial with real life data 138
Prophylaxis of chronic migraine with OnabotulinumtoxinA: experience and evidence in clinical practice 133
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it? 132
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 132
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 131
TYPE 1 INTERFERON RECEPTOR (IFNA-R1). EXPRESSING TH17 LYMPHOCYTES ARE INCREASED DURING MS RELAPSES AND ARE SELECTIVELY INTHBITED BY IFNβ 131
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 131
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 131
Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group 131
Host genetics and gut microbiome: Perspectives for multiple sclerosis 130
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 128
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 127
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. 126
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial 126
The Italian multiple sclerosis register 126
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 126
Is the combination of different treatment responseindicators useful to identify patients with a sub-optimal response to interferon beta? 125
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 124
Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta 123
Atypical presentation of superficial sclerosis successfully treated with iron chelation 123
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. 121
Botulinum toxin A (Dysport) for treatment of sialorrhea in patients with neurologic disorders. 121
Totale 19.235
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.728
article - articoli 0
book - libri 0
conference - conferenze 56.909
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.637
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021355 0 0 0 0 0 0 0 0 0 0 0 355
2021/20222.804 76 67 104 172 147 161 170 161 146 330 553 717
2022/20234.007 415 322 135 405 332 997 298 235 389 135 209 135
2023/20241.953 211 299 117 125 140 243 85 123 12 143 153 302
2024/20255.840 102 213 279 512 1.207 374 157 308 745 386 494 1.063
2025/202611.580 1.136 672 848 1.442 1.290 670 1.799 555 976 1.188 526 478
Totale 35.752